Elizabeth A Coker
Affiliations: | University of Cambridge (UK) |
Area:
computational biology, pharmacology, bioinformaticsGoogle:
"Elizabeth Coker"Parents
Sign in to add mentor| Bissan Al-Lazikani | grad student | 2012-2016 | The Institute of Cancer Research |
| Paul Workman | grad student | 2012-2016 | The Institute of Cancer Research |
| Mathew J. Garnett | post-doc | 2018-2021 | Wellcome Sanger Institute |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Bashi AC, Coker EA, Bulusu KC, et al. (2024) Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations. Cancer Discovery. OF1-OF20 |
| Dunn S, Eberlein C, Yu J, et al. (2022) AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors. Oncogene |
| Coker EA, Stewart A, Ozer B, et al. (2022) Individualised prediction of drug response and rational combination therapy in NSCLC using artificial intelligence enabled studies of acute phosphoproteomic changes. Molecular Cancer Therapeutics |
| Jaaks P, Coker EA, Vis DJ, et al. (2022) Effective drug combinations in breast, colon and pancreatic cancer cells. Nature |
| Winkler C, Armenia J, Jones GN, et al. (2020) SLFN11 informs on standard of care and novel treatments in a wide range of cancer models. British Journal of Cancer |
| Flemington V, Davies EJ, Robinson D, et al. (2020) AZD0364 is a potent and selective ERK1/2 inhibitor which enhances anti-tumour activity in KRAS mutant tumour models when combined with the MEK inhibitor selumetinib. Molecular Cancer Therapeutics |
| Mitsopoulos C, Di Micco P, Fernandez EV, et al. (2020) canSAR: update to the cancer translational research and drug discovery knowledgebase. Nucleic Acids Research |
| Balachander SB, Criscione SW, Byth KF, et al. (2020) AZD4320, a dual inhibitor of Bcl-2 and Bcl-xL, induces tumor regression in hematological cancer models without dose-limiting thrombocytopenia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Gonçalves E, Segura-Cabrera A, Pacini C, et al. (2020) Drug mechanism-of-action discovery through the integration of pharmacological and CRISPR screens. Molecular Systems Biology. 16: e9405 |
| Stewart A, Coker EA, Pölsterl S, et al. (2019) Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in -Mutant Cancers. Molecular Cancer Therapeutics |